Helen Hobbs

American medical researcher

Helen Haskell Hobbs (born May 5, 1952 in Boston, Massachusetts) is an American medical researcher who is professor at the University of Texas Southwestern Medical Center, and a Howard Hughes Medical Institute Investigator, who won a 2016 Breakthrough Prize in Life Sciences and the 2018 Harrington Prize for Innovation in Medicine. Hobbs specializes in the dysregulation of lipid metabolism and how it affects human diseases.2

From Wikipedia’s article on Helen Hobbs (this version), CC BY-SA 4.0.

Born May 5, 1952.1

About

She and Jonathan C. Cohen found that people with hypomorphic PCSK9 mutations had lower LDL-cholesterol levels and were almost immune to heart disease. This finding led to the development of a new class of cholesterol-lowering drugs that mimic the effects of the PCSK9 mutations. She and Cohen also identified the first genetic risk factor for fatty liver disease, a burgeoning health problem that can lead to cirrhosis and liver cancer. Their laboratory has shown that mutation in PNPLA3 causes accumulation of PNPLA3 on lipid droplets, which compromises the mobilization of triglycerides from liver cells. She sits on the Board of Directors at Pfizer.

From Wikipedia’s article on Helen Hobbs, shared under CC BY-SA 4.0.2

Companies

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3